BridgeBio Pharma BBIO Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's short-term investments?
- BridgeBio Pharma (BBIO) reported short-term investments of $60.3M in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's short-term investments?
- Over 5 years (2020 to 2025), BridgeBio Pharma's short-term investments has grown at a -41.4% compound annual growth rate (CAGR), from $251.01M to $17.36M.
- What does short-term investments mean?
- Liquid financial investments that the company expects to convert to cash within one year.
- How do you interpret short-term investments?
- An increase indicates prudent cash management of excess funds, while a decrease may signal the use of these funds to cover operating expenses.
- How does short-term investments compare across companies?
- Commonly held by companies with significant capital raises to preserve purchasing power against inflation.